|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for SLCO1B1(NM_006446.4) Search again
Product ID:
HQP000720
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
HBLRR, LST-1, LST1, OATP-C, OATP1B1, OATP2, OATPC, SLC21A6
Gene Description:
solute carrier organic anion transporter family member 1B1
Target Gene Accession:
NM_006446.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes a liver-specific member of the organic anion transporter family. The encoded protein is a transmembrane receptor that mediates the sodium-independent uptake of numerous endogenous compounds including bilirubin, 17-beta-glucuronosyl estradiol and leukotriene C4. This protein is also involved in the removal of drug compounds such as statins, bromosulfophthalein and rifampin from the blood into the hepatocytes. Polymorphisms in the gene encoding this protein are associated with impaired transporter function. [provided by RefSeq].
Gene References into function
- The promoter of SLC21A6 gene was characterized and regulated by HNF 1alpha.
- Genetic polymorphisms: allele frequencies in the Japanese population and functional analysis
- A naturally occurring mutation in the gene causes impaired membrane localization of the hepatocyte uptake transporter
- human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
- a role for OATP2 in hepatocyte bilirubin transport is unlikely
- commonly occurring single-nucleotide polymorphisms in OATP-C, such as T521C (Val174Ala), are likely to be associated with altered pharmacokinetics of pravastatin
- In heterozygous carriers the pharmacokinetics of pravastatin were higher compared to non-carriers.
- neonates who carry the 211 and 388 variants in the UGT1A1 and OATP 2 genes, respectively, as well as feed with breast milk are at high risk to develop severe hyperbilirubinemia.
- Inhibition of OATP1B1 is an important mechanism for drug-induced unconjugated hyperbilirubinemia.
- UGT1A1, OATP2 and G6PD genes have roles in genetic predisposition to unconjugated hyperbilirubinemia
- Increased exposures of OATP1B1 substrates might be expected in individuals who have the poor transporter phenotype or are treated with an OATP1B1 inhibitor
- single nucleotide polymorphisms has been proposed to cause functional alternations in OATP1B1 with shown consequences for the pharmacokinetics of drugs that are OATP1B1 substrates
- OATP1B1 play an important roles in CDCA uptake into the liver.
- SLCO1B1 haplotypes seem to play a role in basal cholesterol homeostasis.
- Sequence variations of SLCO1B1 occur at high frequencies in the Caucasian population.
- SLCO1B1 polymorphism does not affect the extent of induction of hepatic CYP3A4 by rifampicin.
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin.
- results indicate that OATP1B3/OATP-8 and OATP1B1/OATP-C most likely function as bidirectional facilitated diffusion transporters and that GSH is not a substrate or activator of their transport activity.
- We found eight polymorphic variants that differed in genotypic and allelic frequencies between the Chinese, Malay and Indian populations.
- The 521T-->C polymorphism of SLCO1B1 appears to modulate significantly the total cholesterol-lowering efficacy of pravastatin in Chinese patients with CHD.
- Although the SLCO1B1 polymorphism was found to have a significant effect on the pharmacokinetics of pitavastatin, a nonsynonymous ABCG2 variant, 421C>A, did not appear to be associated with the altered pharmacokinetics of pitavastatin.
- Bosentan uptake into Chinese hamster ovary cells expressing human OATP1B1 or OATP1B3, and was efficiently inhibited by cyclosporin A, rifampicin, and to a lesser extent by sildenafil.
- Suggest a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations.
- cAMP-PKA regulation of OATPC membrane expression involves the Golgi complex.
- HNF1alpha is an essential regulator of OATP1B1 mRNA expression and thus the level of HNF1alpha expression is one of the major determinants of interindividual variability in OATP1B1 mRNA expression.
- Genetic polymorphism in SLCO1B1 is a major determinant of interindividual variability in the serum bilirubin level.
- Data demonstrated that the frequent SLCO1B1 SNP c.1929A>C had no effect on the hepatic OATP1B1 protein expression and on the transport properties.
- most common allele was SLCO1B1*1b, while SLCO1B1*5 was rare or abse
- selective pressure may have acted on SLCO1B1 during human dispersal favoring low-activity variants in the north
- Indicated genetic variation in SLCO1B1 in Japanese population.
- A set of double transfectants expressing OATP1B3 combined with OAT1B1 can be used as a tool for rapid identification of hepatic uptake and efflux transporters of many organic anions that are substrates of OATP1B1 or OATP1B3.
- results demonstrate a high sequence variability of OATP1B1 within different popuations
- SLCO1B1 polymorphism had no significant effect on the plasma pharmacokinetics or pharmacodynamics of nateglinide or its M7 metabolite.
- Alterations of OATP1BB1 function by oral antidiabetic drugs have to be considered as potential mechanisms underlying drug-drug interactions.
- Pregnane X receptor ligands, by inhibiting OATP1B1-mediated uptake, can lead to drug-drug interactions at the transporter level.
- Substrate dependency in the consequences of the SLCO1B1*15 variant could modulate the effect of SLCO1B1 polymorphism on the disposition of pitavastatin and pravastatin.
- OATP1B1-Ala174 displays decreased transport activity and thereby gives rise to higher bilirubin, estrone sulfate, and T4 sulfate levels in carriers of this polymorphism.
- Pharmacokinetics of ezetimibe is influenced by OATP1B1 polymorphisms in healthy participants after single dose administration.
- Eight nonsynonymous OATP1B1 gene variants were detected in children with hereditary hyperbilirubinemia; degree of genetic heterogeneity and variant coexpression across OATP1B1 gene points to polygenic nature of this disease.
- SLCO1B1 polymorphism is associated with Pharmacokinetic interaction between pravastatin and olmesartan.
- We have identified common variants in SLCO1B1 that are strongly associated with an increased risk of statin-induced myopathy.
- The common *14 allele of OATP1B1, which is distinguished by the presence of the c.463C>A polymorphism, is associated with enhanced lipid-lowering efficacy in this study.
- low activity SLCO1B1 c.521CC genotype is associated with an increased cholesterol synthesis rat
- The extent of gemfibrozil-repaglinide interaction depends on SLCO1B1 genotype.